Advertisement

Topics

Latest "Boehringer Ingelheim Corporation" News Stories - Page: 20

04:53 EDT 22nd March 2019 | BioPortfolio

Here are the most relevant search results for "Boehringer Ingelheim Corporation" found in our extensive news archives from over 250 global news sources.

More Information about Boehringer Ingelheim Corporation on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Boehringer Ingelheim Corporation for you to read. Along with our medical data and news we also list Boehringer Ingelheim Corporation Clinical Trials, which are updated daily. BioPortfolio also has a large database of Boehringer Ingelheim Corporation Companies for you to search.

Showing "Boehringer Ingelheim Corporation" News Articles 476–500 of 988

Probably Relevant

Orion and Bayer jointly present new data in prostate cancer from the Darolutamide ARAMIS -study

Orion Corporation                                                        Press Release 5 February 2019 at 3.00 p.m. EET Orion and Bayer jointly present new data in prostate cancer from the Darolutamide ARAMIS -study First presentation of data from the pivotal Phase III ARAMIS trial with the investigational compound daroluta...


Aino Health AB (publ): Aino HealthManager deployed for global company

    18 February 2019  Aino Health's SaaS solution HealthManager has been deployed in two countries for a global company in customer service. It is a joint implementation project conducted by the client and Aino Health for 500 users. The implementation encompasses several client-tailored functionalities for automatic data transfer, adaptation to national legislation, vari...

Johanna Ivaska has been appointed Head & Vice President of Oncology Research in Orion Corporation

 ORION CORPORATION                                            PRESS RELEASE                      10 SEPTEMBER 2018 Johanna Ivaska has been appointed Head & Vice President of Oncology Research in Orion Corporation Johanna Ivaska (born 1972), Academy Professor of Biochemistry has been appointed Head & Vice ...


Aino Health AB (publ): Aino Health's solution go-live for Multi Contact GmbH

    2019-02-04 Aino Health go-live with its SaaS solution Aino HealthManager for Multi Contact's operations in Germany. This is a joint implementation project with MultiContact and Aino Health that is comprised of process definition, technical IT integration, training of management as well as communications. This is the second launch of importance in Germany for Aino Health....

INVENTIVA : Inventiva launches an independent working group to help increase NASH awareness and establish best practices for its treatment

Inventiva launches an independent working group to help increase NASH awareness and establish best practices for its treatment Daix (France), September 24th, 2018 - Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis...

LIDDS adds another Scandinavian clinic to the NZ-DTX-001 clinical trial

UPPSALA, SWEDEN - LIDDS AB (publ) has received approval from the Danish Medicines Agency (DKMA) to conduct its Phase I NZ-DTX-001 clinical trial. The Danish study is in addition to the Phase I NZ-DTX-001 clinical trial being conducted at the Karolinska University Hospital. The aim of the dose escalation clinical trial is to assess the tolerability and safety of intratumoral injections of N...

Nexstim Plc Publishes 2018 Annual Report

Company announcement, Helsinki, 04.03.2019 at 09.15 Finnish time (EET) Nexstim Plc Publishes 2018 Annual Report Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depression Disorder (MDD), an...

Santhera's Board of Directors Submits Amended Proposal to its Extraordinary General Meeting on December 11, 2018

Santhera Pharmaceuticals Holding AG / Santhera's Board of Directors Submits Amended Proposal to its Extraordinary General Meeting on December 11, 2018 . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Pratteln, Switzerland, December 10, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that its Board o...

Press release: Terveystalo continues to grow its footprint in well-being services: Kuntoutumisasema OTE Oy to become part of Terveystalo

On 14 December, Terveystalo signed a contract on acquiring the operations of Kuntoutumisasema OTE Oy. The acquisition is already fourth deal in the area of well-being services during this year. The company's employees will be transferred to Terveystalo as old employees and the operations will continue on the same premises as before. Kuntoutumisasema OTE Oy provides physiotherapy, m...

Dicerna Announces Closing of Global Licensing and Research Collaboration with Eli Lilly and Company

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the closing of the global licensing and research collaboration between Dicerna and Eli Lilly and Company following clearance under t

FIT Biotech Oy: FIT Biotech expands R&D pipeline

FIT Biotech Oy  Company release 22.11.2018 at 08:30 AM EET FIT Biotech expands R&D pipeline FIT Biotech Oy ("FIT Biotech", "Company", FITBIO: FN Finland) announced that it has included two new candidates to its R&D portfolio. The candidates follow the Company's strategy of focusing on gene-based treatments that are built on its GTU® and gtGTU techn...

Global Blockbuster Drugs Market 2015 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts [Report Updated: 08102018] Prices from USD $1390

The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025.'Global Blockbuster Drugs Market 2015 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts presents an indepth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most uptodate...

Novo Nordisk settles US patent litigation case on Victoza® (liraglutide) with Teva

Bagsværd, Denmark, 18 March 2019 - Novo Nordisk today announced that a settlement between Novo Nordisk and Teva Pharmaceuticals USA, Inc. (Teva) has been reached on the US patent litigation case for Victoza® (liraglutide). Consequently, Teva is licensed to launch a generic version of Victoza® as of 22 December 2023. Under certain circumstances Teva could launch a generic ...

Merger between Eckert & Ziegler BEBIG SA and Eckert & Ziegler Strahlen- und Medizintechnik AG - Announcement of the approval of the merger by the Extraordinary General Shareholders' Meeting of BEBIG.

Press release  REGULATED INFORMATION Seneffe, Belgium, December 21, 2018. Shareholders' general meeting The EGM of BEBIG approved on 21 December 2018 (i) the modification of the financial year of BEBIG and (ii) the cross-border merger by absorption of BEBIG by EZAG, pursuant to which the absorbed company (BEBIG) will be absorbed by the absorbing company (EZAG) and all assets an...

Inventiva Announces Poster Presentation on Its YAP/TEAD Inhibitor Program at the EORTC-NCI-AACR Symposium in Dublin

               Inventiva Announces Poster Presentation on Its YAP/TEAD Inhibitor Program at the EORTC-NCI-AACR Symposium in Dublin Recent results reveal potential of oral small molecules in pre-clinical development by Inventiva targeting the YAP/TEAD pathway as a potential therapy in the treatment of mesothelioma and non-small cell lung cancer Daix (France), November...

Xbrane Biopharma presents nomination committee

Press release2018-11-26   In accordance with the principles of the nomination committee of Xbrane Biopharma AB ("Company" or "Xbrane"), adopted at the Annual General Meeting on 24 May 2018, the Nomination Committee shall consist of up to four members appointed by the three largest shareholders as of September 30, 2018. The fourth member shall be the chairman o...

Numab Appoints Immunotherapy Pioneer Ignacio Melero as Scientific Advisor

Company progresses development of tri-specific IO therapeutic ND021 ND021 is designed to improve the risk-benefit profile over conventional IO combination therapies Numab Therapeutics AG, a biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer, today announced it appointed Dr. Ignacio Javi...

MediaPlanet and Dante Labs Team Up to Highlight the Role of Whole Genome Sequencing within Rare Diseases

Mediaplanet’s Rare Diseases campaign found within USA TODAY and online highlights approved treatment options along with new investigational research and innovations in rare diseases. NEW YORK (PRWEB) September 14, 2018 Today, Mediaplanet announces the launch of this September’s edition of “Rare Diseases." This campaign will showcase the innovative work being done within rare diseases r...

Active Biotech AB - Interim report January - September 2018

                                  Third quarter in brief Active Biotech provides update on laquinimod in Huntington's disease Active Biotech regains global rights to the development and commercialization of laquinimod Data from the LEGATO-HD study of laquinimod in Huntington's disease presented at the EHDN meeting Events after t...

ESPERITE (ESP) : European Select Growth Opportunities Fund subscribes to the 23rd tranche of investment today

Amsterdam, The Netherlands - 30 November 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 23rd   Tranche of EUR 220,000 is issued as a private placement of 22 convertible notes (the "Notes") with a principal amount of EUR 10,000 each, with 592,814 share subscription warrants attached (the "Warrants"), u...

ESPERITE (ESP) : European Select Growth Opportunities Fund subscribes to the 24th tranche of investment today

    Amsterdam, The Netherlands - 10 January 2019 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 24th   Tranche of EUR 230,000 is issued as a private placement of 23 convertible notes (the "Notes") with a principal amount of EUR 10,000 each, with 778,195 share subscription warrants attached (the "Warrants"), under t...

DBV Technologies to Present at the Cantor Global Healthcare Conference

Montrouge, France, September 25, 2018 DBV Technologies to Present at the Cantor Global Healthcare Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Susanna Mesa, Chief Business Officer, will present at the Cantor Global Healthcare Conference on Tuesday, October ...

DBV Technologies: Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF REGULATED INFORMATIONMontrouge, France, January 17, 2019 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between...

Altasciences Completes Bioanalytical Laboratory Expansion

LAVAL, Quebec, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Altasciences is excited to announce the completion of their laboratory expansion. The additional space will be dedicated to ligand binding and cell-based assays. Altasciences' bioanalytical services continue to grow, and the added, state-of-the-art lab area ensures capacity to continue delivering quality bioanalysis solutions to both thei...

Nexstim Plc's Financial Information in 2019

Company announcement, Helsinki, 21 December 2018 at 09.00 Nexstim Plc's Financial Information in 2019 Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depression Disorder (MDD), will publish the following financial information i...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks